What is IXHL stock price today?

IXHL (Incannex Healthcare Inc) stock is trading at $3.56 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IXHL stock going up or down today?

IXHL stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IXHL stock now?

The decision to buy IXHL depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IXHL a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IXHL based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IXHL stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IXHL is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IXHL's P/E ratio?

P/E ratio data for IXHL will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IXHL's market cap?

IXHL (Incannex Healthcare Inc) has a market capitalization of $0.05 billion, making it a small-cap stock.

What is IXHL's price to book ratio?

IXHL trades at a price-to-book (P/B) ratio of 0.68, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IXHL pay dividends?

IXHL does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IXHL's dividend yield?

IXHL does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IXHL stock a good long-term investment?

IXHL's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IXHL's revenue growth rate?

IXHL has shown revenue growth of -1.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for IXHL are available on our dashboard with complete income statement analysis.

What are the risks of investing in IXHL?

Key risks for IXHL include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IXHL compare to its competitors?

Compare IXHL to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IXHL's performance and positioning.

What is IXHL's stock price target for 2026?

Our AI model provides price targets for IXHL based on fundamental analysis: Bull case $4.62 (+30%), Base case $4.09 (+15%), Bear case $3.20 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IXHL?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IXHL. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IXHL's next earnings report?

IXHL reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IXHL - Incannex Healthcare Inc

NYSE * Health Care * Pharmaceuticals

$3.56

+$0.01 (+0.14%)

About Incannex Healthcare Inc

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

IXHL Key Statistics

Market Cap

$49.47M

P/B Ratio

0.68

EPS

$-22.08

Revenue Growth

-1.0%

Employees

How IXHL Compares to Peers

IXHL is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 1

Margin Rank

N/A

of 1

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
IXHL(This stock)	$49.47M	N/A	-1%	0.0%	-
AMZNAmazon Com	$2.68T	34.7	0%	0.1%	vs AMZN

Incannex Healthcare Inc Company Information

Headquarters: Australia
Website: www.incannex.com
Sector: Health Care
Industry: Pharmaceuticals

Data Updated: April 15, 2026 at 8:16 AM EDT

Ready to invest in IXHL?

Commission-free trading available. Affiliate links.

IXHL Lician Score

5% confidence

5.0/10

Neutral

IXHL has a Lician Score of 5/10 (Average). The stock shows average characteristics across all dimensions.

value

5.0

growth

4.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates IXHLacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

IXHL Financial Snowflake

5-axis analysis across key investment dimensions

4.8/10

Neutral

5.0

Value

Valuation vs. sector peers

4.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for IXHL

Dashboard

Enter a ticker to analyze